Smart Capital, Leveraged Science: How VCs Unlock Biotech Potential
28 May 2025
13:00 -15:00
Times are shown in local time.
Open to: All
Cambridge Judge Business School
Trumpington St
Cambridge
CB2 1AG
United Kingdom
Go to events page
Category: Business School events
Demystifying due diligence, syndication shifts, and the unique edge of life sciences VC
Join us on 28 May 2025 for an in-person panel discussion exploring how life sciences venture capital firms unlock biotech potential. This event collaboration between the University of Cambridge Judge Business School and Forbion, brings together leading voices from venture capital, biotech entrepreneurship, and institutional investment.
Through dynamic conversation and in-depth case studies, the panel will unpack the due diligence process from a VC lens, evaluate the implications of evolving syndication models, and explore why life sciences continue to out perform other VC areas of investment. Whether you are a biotech founder, investor, academic or policy expert, this event offers a timely look at the forces shaping the future of biotech innovation.
Speakers
- Sander Slootweg, Managing Partner Forbion
- Mihriban Tuna, PhD CEO Immutrin
- Carmine Cicelli, PhD Director Direct Investments (Life Sciences) at British Business Bank
- Nektarios (Aris) Oriaopoulos, PhD Professor of Operations & Technology Management, Cambridge Judge Business School, University of Cambridge
Register
* This registration link is to an independent website which is not under our control, and we are not responsible for and have not checked or approved the data protection or privacy policies.